EXACT Therapeutics Past Earnings Performance
Past criteria checks 0/6
EXACT Therapeutics's earnings have been declining at an average annual rate of -13.7%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been declining at an average rate of 108.7% per year.
Key information
-13.7%
Earnings growth rate
-9.2%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -108.7% |
| Return on equity | -107.2% |
| Net Margin | -1,084,201.2% |
| Next Earnings Update | 19 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How EXACT Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -48 | 23 | 0 |
| 30 Sep 23 | 0 | -42 | 21 | 0 |
| 30 Jun 23 | 0 | -36 | 20 | 0 |
| 31 Mar 23 | 0 | -38 | 17 | 0 |
| 31 Dec 22 | 0 | -40 | 15 | 0 |
| 30 Sep 22 | 0 | -45 | 11 | 0 |
| 30 Jun 22 | 0 | -49 | 7 | 0 |
| 31 Mar 22 | 0 | -54 | 13 | 0 |
| 31 Dec 21 | 0 | -59 | 19 | 0 |
| 30 Sep 21 | 0 | -58 | 23 | 0 |
| 30 Jun 21 | 0 | -58 | 27 | 0 |
| 31 Mar 21 | 0 | -46 | 21 | 0 |
| 31 Dec 20 | 0 | -33 | 15 | 0 |
| 31 Dec 19 | 0 | -15 | 6 | 0 |
| 31 Dec 18 | 6 | -8 | 6 | 0 |
| 31 Dec 17 | 8 | -5 | 4 | 0 |
Quality Earnings: 56F is currently unprofitable.
Growing Profit Margin: 56F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 56F is unprofitable, and losses have increased over the past 5 years at a rate of 13.7% per year.
Accelerating Growth: Unable to compare 56F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 56F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: 56F has a negative Return on Equity (-107.17%), as it is currently unprofitable.